JPMorgan's Downgrade#
JPMorgan has lowered its rating for Agilon Health Inc (NYSE:AGL) from Neutral to Underweight. The new price target is set at $21.00, significantly below the current trading price of $25.69. The company is scheduled to report its earnings on May 12.
Reasons for Downgrade#
Analyst Lida Gill pointed out that Agilon Health needs to address ongoing high utilization rates and work on rebuilding trust with investors. The firm emphasized that effective execution and management credibility are crucial as Agilon Health aims to reposition itself for the future, particularly looking towards 2027. Over the past year, the company has reported a loss of $24.48 per share and has a negative gross profit margin of -2.7%.
Future Outlook#
JPMorgan believes it may take several quarters for Agilon Health to demonstrate the necessary improvements that would convince investors of a significant earnings increase in the coming years. The firm noted that the company expects to make operational enhancements, including better contracting and clearer cost trends, as it approaches 2026.
Recent Developments#
Despite the downgrade, Agilon Health's shares have surged more than 270% since March 31, largely due to favorable updates regarding Medicare Advantage rates and a recent 1-for-25 reverse stock split. Year-to-date, the stock is up 71.8%. The company has also appointed Tim O’Rourke as its new CEO, effective May 7, who will replace Ronald A. Williams while he continues as Chairman of the Board. Additionally, analyst firm Benchmark has raised its price target for Agilon Health to $13.00, maintaining a Buy rating, while Bernstein SocGen Group has reiterated a Market Perform rating with a price target of $22.04, reflecting cautious optimism about the company's long-term growth potential.